Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 378 participants.
Also called NCT03145675
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 378 participants
- Registry
-
NCT03145675
-
- Other papers using this trial's data
- Trough anticoagulant levels of high-dose versus standard-dose intravenous enoxaparin in patients undergoing trans-radial coronary angiography alone
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03145675. Randomized; no masking; primary purpose treatment. Start 2017-05-12 (actual); primary completion 2022-04-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)
- Acronym
- OPTIENOX-PCI
- Condition
- Coronary Artery Disease
- Condition
- Percutaneous Coronary Intervention
- Intervention (Drug)
- Enoxaparin (Staged-dose PCI Group)
- Intervention (Drug)
- Enoxaparin (Single-dose PCI Group)
- Intervention (Drug)
- Enoxaparin (High-dose Group)
- Intervention (Drug)
- Enoxaparin (Standard-dose Group)
- Lead sponsor
- Peking Union Medical College Hospital
Record details
- Record id
cardio:ct-nct03145675- Content hash
5d17257010114f1f62174914ebc9ecdb8db467865af7723a5d61e24ceff3b26b